Clene Inc.

NASDAQ:CLNN

Biotechnology

Healthcare
$3.66 +1.35%

+$0.08 today

Market cap
$52.70M
Beta
0.92
P/E (TTM)
-2.1
EPS (TTM)
-$2.88
52W Low $3.25High $13.50

Volume 0.12M

Average 0.50M

CLNN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Clene Inc.NASDAQ: CLNN

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 39.6% from a year ago

Cash & equivalents stood at $5.94M at the end of Q1 FY2026, down 39.6% from a year earlier and up 14.5% from the prior quarter. Over 3 fiscal years it compounded at -34.3% a year.

Context

  • Cash & equivalents amounted to 27.4% of total assets at the end of Q1 FY2026, down 11.4 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -39.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.94M+14.5% QoQ
Last fiscal yearDec 2025
$5.19M-57.3% YoY
Year agoMar 2025
$9.83M-39.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-39.6%——
1 year-57.3%——
3-year CAGR-34.3%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
5.19M USD
Year-over-year change
-57.3%
4-year CAGR
-43.3%

Cash & Equivalents vs competitors

How CLNN compares with its peers on the latest reported figures

  • CLNN's Mar 2026 cash & equivalents of $5.94M is the lowest of the 11 companies compared; the peer median is $44.53M.
  • Its year-over-year change of -39.6% is the 6th highest of 11, against a peer median of -45.0%.
  • Cash & equivalents amounts to 27.4% of total assets for CLNN, versus a peer median of 36.1%.
CLNN Competitors Peer median
Cash & Equivalents for CLNN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
OVIDOvid Therapeutics Inc.Mar 2026$94.06M +345.0%-33.6%41.7%
STTKShattuck Labs, Inc.Mar 2026$90.42M +48.5%+4.6%88.5%
MGNXMacroGenics, Inc.Mar 2026$66.52M -54.3%-19.3%30.5%
CNTXContext Therapeutics Inc.Mar 2026$54.53M -39.0%+23.0%92.6%
COYACoya Therapeutics, Inc.Mar 2026$50.72M +42.8%+99.1%95.2%
CNTBConnect Biopharma Holdings LimitedDec 2025$38.35M -51.0%-21.4%68.4%
WHWKWhitehawk Therapeutics IncMar 2026$34.79M -84.7%-1.3%27.3%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$31.93M -23.8%-5.8%12.6%
PLRXPliant Therapeutics, Inc.Mar 2026$22.19M -75.9%+10.5%11.0%
ORMPOramed Pharmaceuticals Inc.Mar 2026$13.2M -82.3%+4.3%4.9%
CLNNClene Inc.Mar 2026$5.94M -39.6%-34.3%27.4%
Peer median (excluding CLNN) $44.53M-45.0%+1.5%36.1%

Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents50.29M18.33M28.82M12.16M5.19M
Short-term Investments04.98M6.18M00
Net Receivables1.61M2.97M1.34M391K590K
Inventory41K43K37K68K37K
Other Current Assets2.45M2.87M2.48M137K139K
Total Current Assets54.58M29.2M38.85M16.16M8.98M
Property, Plant & Equipment (Net)8.42M15.24M13.43M11.12M9.1M
Goodwill00000
Intangible Assets00000
Long-term Investments58K58K058K58K
Tax Assets00000
Other Non-current Assets0058K00
Total Non-current Assets8.48M15.3M13.49M11.18M9.15M
Total Assets63.06M44.49M52.34M27.34M18.13M
Account Payables1.92M3.01M1.5M1.24M892K
Short-term Debt06.42M19.5M359K4.07M
Tax Payables00000
Deferred Revenue520K520K02.67M1.51M
Other Current Liabilities2.05M1.49M2.12M4.08M3.14M
Total Current Liabilities6.03M13.86M25.33M10.29M10.78M
Long-term Debt19.08M19.25M7.15M15.43M13.54M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities20.89M2.56M1.57M6.35M8.16M
Total Non-current Liabilities44.44M27.4M13.62M25.9M24.95M
Total Liabilities50.47M41.26M38.95M36.19M35.72M
Common Stock6K7K13K1K1K
Retained Earnings(163.3M)(193.22M)(242.72M)(282.12M)(308.3M)
Accumulated OCI233K203K199K71K172K
Other Stockholders Equity00000
Minority Interest00000
Total Equity12.6M3.24M13.39M(8.86M)(17.59M)
Total Debt24.04M31.82M32.16M20.84M21.67M
Net Debt(26.25M)13.49M3.34M8.69M16.48M

Clene Inc.

NASDAQ:CLNN

Intrinsic Alpha fair value

Locked

Current Price

$3.66

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.